-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Hepatitis -X- _ O
C -X- _ O
core -X- _ O
protein -X- _ O
is -X- _ O
an -X- _ O
attractive -X- _ O
target -X- _ O
for -X- _ O
HCV -X- _ B-Intervention
vaccine -X- _ I-Intervention
aimed -X- _ O
to -X- _ O
exterminate -X- _ O
HCV -X- _ O
infected -X- _ O
cells. -X- _ O
However -X- _ O
, -X- _ O
although -X- _ O
highly -X- _ O
immunogenic -X- _ O
in -X- _ O
natural -X- _ O
infection -X- _ O
, -X- _ O
core -X- _ O
appears -X- _ O
to -X- _ O
have -X- _ O
low -X- _ O
immunogenicity -X- _ O
in -X- _ O
experimental -X- _ O
settings. -X- _ O
We -X- _ O
aimed -X- _ O
to -X- _ O
design -X- _ O
an -X- _ O
HCV -X- _ B-Intervention
vaccine -X- _ I-Intervention
prototype -X- _ I-Intervention
based -X- _ O
on -X- _ O
core -X- _ O
, -X- _ O
and -X- _ O
devise -X- _ O
immunization -X- _ O
regimens -X- _ O
that -X- _ O
would -X- _ O
lead -X- _ O
to -X- _ O
potent -X- _ O
anti-core -X- _ O
immune -X- _ O
responses -X- _ O
which -X- _ O
circumvent -X- _ O
the -X- _ O
immunogenicity -X- _ O
limitations -X- _ O
earlier -X- _ O
observed -X- _ O
. -X- _ O

METHODS -X- _ O
: -X- _ O
Plasmids -X- _ O
encoding -X- _ O
core -X- _ O
with -X- _ O
no -X- _ O
translation -X- _ O
initiation -X- _ O
signal -X- _ O
( -X- _ O
pCMVcore -X- _ B-Intervention
) -X- _ O
; -X- _ O
with -X- _ O
Kozak -X- _ O
sequence -X- _ O
( -X- _ O
pCMVcoreKozak -X- _ B-Intervention
) -X- _ O
; -X- _ O
and -X- _ O
with -X- _ O
HCV -X- _ O
IRES -X- _ O
( -X- _ O
pCMVcoreIRES -X- _ B-Intervention
) -X- _ O
were -X- _ O
designed -X- _ O
and -X- _ O
expressed -X- _ O
in -X- _ O
a -X- _ O
variety -X- _ O
of -X- _ O
eukaryotic -X- _ O
cells. -X- _ O
Polyproteins -X- _ O
corresponding -X- _ O
to -X- _ O
HCV -X- _ O
1b -X- _ O
amino -X- _ O
acids -X- _ O
( -X- _ O
aa -X- _ O
) -X- _ O
1–98 -X- _ O
and -X- _ O
1–173 -X- _ O
were -X- _ O
expressed -X- _ O
in -X- _ O
E. -X- _ O
coli. -X- _ O
C57BL -X- _ B-Patient
/ -X- _ I-Patient
6 -X- _ I-Patient
mice -X- _ I-Patient
were -X- _ O
immunized -X- _ O
with -X- _ O
four -X- _ B-Intervention
25-μg -X- _ I-Intervention
doses -X- _ I-Intervention
of -X- _ I-Intervention
pCMVcoreKozak -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
pCMV -X- _ I-Intervention
( -X- _ I-Intervention
I -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
BALB -X- _ B-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice -X- _ I-Patient
were -X- _ O
immunized -X- _ O
with -X- _ O
100 -X- _ B-Intervention
μg -X- _ I-Intervention
of -X- _ I-Intervention
either -X- _ I-Intervention
pCMVcore -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
pCMVcoreKozak -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
pCMVcoreIRES -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
empty -X- _ I-Intervention
pCMV -X- _ I-Intervention
( -X- _ I-Intervention
II -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Lastly -X- _ O
, -X- _ O
BALB -X- _ B-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice -X- _ I-Patient
were -X- _ O
immunized -X- _ O
with -X- _ O
20 -X- _ B-Intervention
μg -X- _ I-Intervention
of -X- _ I-Intervention
core -X- _ I-Intervention
aa -X- _ I-Intervention
1–98 -X- _ I-Intervention
in -X- _ I-Intervention
prime -X- _ I-Intervention
and -X- _ I-Intervention
boost -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
with -X- _ I-Intervention
100 -X- _ I-Intervention
μg -X- _ I-Intervention
of -X- _ I-Intervention
pCMVcoreKozak -X- _ I-Intervention
in -X- _ I-Intervention
prime -X- _ I-Intervention
and -X- _ I-Intervention
20 -X- _ I-Intervention
μg -X- _ I-Intervention
of -X- _ I-Intervention
core -X- _ I-Intervention
aa -X- _ I-Intervention
1–98 -X- _ I-Intervention
in -X- _ I-Intervention
boost -X- _ I-Intervention
( -X- _ I-Intervention
III -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Antibody -X- _ O
response -X- _ O
, -X- _ O
[ -X- _ O
( -X- _ O
3 -X- _ O
) -X- _ O
H -X- _ O
] -X- _ O
-T-incorporation -X- _ O
, -X- _ O
and -X- _ O
cytokine -X- _ O
secretion -X- _ O
by -X- _ O
core -X- _ O
/ -X- _ O
core -X- _ O
peptide-stimulated -X- _ O
splenocytes -X- _ O
were -X- _ O
assessed -X- _ O
after -X- _ O
each -X- _ O
immunization. -X- _ O
RESULTS -X- _ O
: -X- _ O
Plasmids -X- _ O
differed -X- _ O
in -X- _ O
core-expression -X- _ O
capacity -X- _ O
: -X- _ O
mouse -X- _ O
fibroblasts -X- _ O
transfected -X- _ O
with -X- _ O
pCMVcore -X- _ O
, -X- _ O
pCMVcoreIRES -X- _ O
and -X- _ O
pCMVcoreKozak -X- _ O
expressed -X- _ O
0.22 -X- _ O
± -X- _ O
0.18 -X- _ O
, -X- _ O
0.83 -X- _ O
± -X- _ O
0.5 -X- _ O
, -X- _ O
and -X- _ O
13 -X- _ O
± -X- _ O
5 -X- _ O
ng -X- _ O
core -X- _ O
per -X- _ O

cell -X- _ O
, -X- _ O
respectively. -X- _ O
Single -X- _ B-Outcome
immunization -X- _ I-Outcome
with -X- _ I-Outcome
highly -X- _ I-Outcome
expressing -X- _ I-Outcome
pCMVcoreKozak -X- _ I-Outcome
induced -X- _ I-Outcome
specific -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
and -X- _ I-Outcome
IL-2 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
weak -X- _ I-Outcome
antibody -X- _ I-Outcome
response. -X- _ I-Outcome
Single -X- _ B-Outcome
immunization -X- _ I-Outcome
with -X- _ I-Outcome
plasmids -X- _ I-Outcome
directing -X- _ I-Outcome
low -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
core -X- _ I-Outcome
expression -X- _ I-Outcome
induced -X- _ I-Outcome
similar -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
cytokines -X- _ I-Outcome
, -X- _ I-Outcome
strong -X- _ I-Outcome
T-cell -X- _ I-Outcome
proliferation -X- _ I-Outcome
( -X- _ I-Outcome
pCMVcoreIRES -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
antibodies -X- _ I-Outcome
in -X- _ I-Outcome
titer -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
pCMVcore -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Boosting -X- _ B-Outcome
with -X- _ I-Outcome
pCMVcoreKozak -X- _ I-Outcome
induced -X- _ I-Outcome
low -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
core-specific -X- _ I-Outcome
T-cell -X- _ I-Outcome
proliferation -X- _ I-Outcome
and -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
secretion -X- _ I-Outcome
that -X- _ O
subsided -X- _ O
after -X- _ O
the -X- _ O
3rd -X- _ O
plasmid -X- _ O
injection. -X- _ O
The -X- _ O
latter -X- _ O
also -X- _ O
led -X- _ O
to -X- _ O
a -X- _ O
decrease -X- _ B-Outcome
in -X- _ I-Outcome
specific -X- _ I-Outcome
IL-2 -X- _ I-Outcome
secretion. -X- _ I-Outcome
The -X- _ O
best -X- _ B-Outcome
was -X- _ I-Outcome
the -X- _ I-Outcome
heterologous -X- _ I-Outcome
pCMVcoreKozak -X- _ I-Outcome
prime -X- _ I-Outcome
/ -X- _ I-Outcome
protein -X- _ I-Outcome
boost -X- _ I-Outcome
regimen -X- _ I-Outcome
that -X- _ O
generated -X- _ O
mixed -X- _ O
Th1 -X- _ O
/ -X- _ O
Th2-cellular -X- _ O
response -X- _ O
with -X- _ O
core-specific -X- _ O
antibodies -X- _ O
in -X- _ O
titer -X- _ O
≥ -X- _ O
3 -X- _ O
× -X- _ O
10 -X- _ O
( -X- _ O
3 -X- _ O
) -X- _ O
. -X- _ O

CONCLUSION -X- _ O
: -X- _ O
Thus -X- _ O
, -X- _ O
administration -X- _ O
of -X- _ O
highly -X- _ B-Intervention
expressed -X- _ I-Intervention
HCV -X- _ I-Intervention
core -X- _ I-Intervention
gene -X- _ I-Intervention
, -X- _ O
as -X- _ O
one -X- _ O
large -X- _ O
dose -X- _ O
or -X- _ O
repeated -X- _ O
injections -X- _ O
of -X- _ O
smaller -X- _ O
doses -X- _ O
, -X- _ O
may -X- _ O
suppress -X- _ B-Outcome
core-specific -X- _ I-Outcome
immune -X- _ I-Outcome
response. -X- _ I-Outcome
Instead -X- _ O
, -X- _ O
the -X- _ O
latter -X- _ O
is -X- _ O
induced -X- _ O
by -X- _ O
a -X- _ O
heterologous -X- _ O
DNA -X- _ O
prime -X- _ O
/ -X- _ O
protein -X- _ O
boost -X- _ O
regimen -X- _ O
that -X- _ O
circumvents -X- _ O
the -X- _ O
negative -X- _ O
effects -X- _ O
of -X- _ O
intracellular -X- _ O
core -X- _ O
expression -X- _ O
. -X- _ O

